DANAZOL: AN ANTIGONADOTROPHIC AGENT IN THE TREATMENT OF RECURRENT PELVIC AND INTESTINAL ENDOMETRIOSIS

M Ingerslev
Acta obstetricia et gynecologica Scandinavica · 1977 · vol. 56(4) , pp. 343–346 · doi:10.3109/00016347709154990 · PMID:602701 · W2161009205
article OA: closed CC0 ⤵ 9 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

Danazol at 400 mg daily for six months was administered to six women with recurrent pelvic and intestinal endometriosis, showing satisfactory initial results except in one case with adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Six cases of pelvic endometriosis were treated with Danazol 400 mg daily for six months. In four of these cases, intestinal endometriosis of varying severity was also present. The initial results were very satisfactory except in one case with adenomyosis and continuous spotting. Follow-up after cessation of treatment suggests that in some cases a further period of treatment will be necessary.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosisadenomyosis

MeSH descriptors

Danazol Endometriosis Intestinal Neoplasms Pelvic Neoplasms Pregnadienes Administration, Oral Adult Danazol Danazol Drug Evaluation Endometriosis Endometriosis Endometrium Endometrium Female Follow-Up Studies Humans Intestinal Neoplasms Neoplasm Recurrence, Local Pelvic Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (6)

Cited by (9)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-14T05:58:58.463083+00:00
License: CC0 · commercial use OK